相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+or 2+
Louis Fehrenbacher et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low-Expressing Advanced Breast Cancer: Results From a Phase Ib Study
Shanu Modi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Paolo Tarantino et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
Eleonora Nicolo et al.
CURRENT OPINION IN ONCOLOGY (2020)
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
F. Cardoso et al.
ANNALS OF ONCOLOGY (2019)
Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
Joseph A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
Udai Banerji et al.
LANCET ONCOLOGY (2019)
HER2 and Breast Cancer - A Phenomenal Success Story
Daniel F. Hayes
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
H. J. Burstein et al.
ANNALS OF ONCOLOGY (2019)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
Erik J. Blok et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
J. A. Sparano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017
G. Curigliano et al.
ANNALS OF ONCOLOGY (2017)
Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Nikiforita Poulakaki et al.
BREAST (2016)
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Jacquie H. Chirgwin et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer
Holm Eggemann et al.
ENDOCRINE-RELATED CANCER (2015)
Adherence to Endocrine Therapy in Breast Cancer Adjuvant and Prevention Settings
Rowan T. Chlebowski et al.
CANCER PREVENTION RESEARCH (2014)
US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status
Nadia Howlader et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Single-Cell Quantitative HER2 Measurement Identifies Heterogeneity and Distinct Subgroups within Traditionally Defined HER2-Positive Patients
Matthew D. Onsum et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Moderate Immunohistochemical Expression of HER-2 (2+) Without HER-2 Gene Amplification Is a Negative Prognostic Factor in Early Breast Cancer
Valentina Rossi et al.
ONCOLOGIST (2012)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
Kathy S. Albain et al.
LANCET ONCOLOGY (2010)
Lobular breast carcinoma and its variants
Emad A. Rakha et al.
SEMINARS IN DIAGNOSTIC PATHOLOGY (2010)
Even Low-level HER2 Expression May be Associated With Worse Outcome in Node-positive Breast Cancer
Michael Z. Gilcrease et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
Biology, prognosis and response to therapy of breast carcinomas according to HER2 score
S. Menard et al.
ANNALS OF ONCOLOGY (2008)
aTTom (adjuvant Tamoxifen-To offer more?): Randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer-Preliminary results
R. G. Gray et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
V Guarneri et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome
G Arpino et al.
BREAST CANCER RESEARCH (2004)
分享论文
